Prooxidant mechanisms in iron overload cardiomyopathy

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Cheng, Ching Feng ^a,b   Lian, Wei Shiung ^a,b  

^a TZU CHI UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ARACHIDONIC ACID; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; CYCLOSPORIN A; DOXORUBICIN; EFONIDIPINE; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; IRON; IRON CHELATING AGENT; MONOCYTE CHEMOTACTIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; THROMBOPLASTIN; THROMBOXANE A2; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA; VERAPAMIL;

ACUTE HEART INFARCTION; BETA THALASSEMIA; BRADYCARDIA; CARDIOMYOPATHY; CARDITIS; CHELATION THERAPY; ELECTRIC CONDUCTIVITY; FIBROBLAST; FIBROSING ALVEOLITIS; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTILITY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HUMAN; HYPOTENSION; INOTROPISM; IRON CHELATION; IRON OVERLOAD; IRON TRANSPORT; MACROPHAGE; MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; REVIEW; SIGNAL TRANSDUCTION; THALASSEMIA; METABOLISM; PHYSIOLOGY;

CARDIOMYOPATHIES; HUMANS; IRON; IRON OVERLOAD; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 84890098446     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/740573     Document Type: Review

References (65)

1. Zurlo M. G., Stefano D. P., Borgna-Pignatti C., Di Palma A., Piga A., Melevendi C., Di Gregorio F., Burattini M. G., Terzoli S., Survival and causes of death in thalassaemia major. The Lancet 1989 2 8653 27 30 2-s2.0-0024337363 (Pubitemid 19158169)
2. Olivieri N. F., Brittenham G. M., Iron-chelating therapy and the treatment of thalassemia. Blood 1997 89 3 739 761 2-s2.0-0031001278 (Pubitemid 27121266)
3. Thomas E. D., Buckner C. D., Sanders J. E., Marrow transplantation for thalassaemia. The Lancet 1982 2 8292 227 229 2-s2.0-0019967483 (Pubitemid 12081767)
4. Roberts I., Current status of allogeneic transplantation for haemoglobinopathies. British Journal of Haematology 1997 98 1 1 7 2-s2.0-0030787426 (Pubitemid 27348786)
5. Third internationalsymposium on BMT in thalassemia. Bone Marrow Transplant 1997 19 supplement 2 1 206 10.1038/sj.bmt.1700655
6. Giardini C., Galimberti M., Lucarelli G., Polchi P., Angelucci E., Baronciani D., Gaziev D., Erer B., La Nasa G., Barbanti I., Muretto P., Desferrioxamine therapy accelerates clearance of iron deposits after bone marrow transplantation for thalassaemia. British Journal of Haematology 1995 89 4 868 873 2-s2.0-0028941571
7. Liu P., Olivieri N., Iron overload cardiomyopathies: new insights into an old disease. Cardiovascular Drugs and Therapy 1994 8 1 101 110 2-s2.0-0028318993 10.1007/BF00877096 (Pubitemid 24164805)
8. Aldouri M. A., Wonke B., Hoffbrand A. V., Flynn D. M., Ward S. E., Agnew J. E., Hilson A. J. W., High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematologica 1990 84 3 113 117 2-s2.0-0025186342 (Pubitemid 20361934)
9. Hou J. W., Wu M. H., Lin K. H., Lue H.-C., Prognostic significance of left ventricular diastolic indexes in β-thalassemia major. Archives of Pediatrics and Adolescent Medicine 1994 148 8 862 866 2-s2.0-0028122440 (Pubitemid 24243782)
10. Engle M. A., Erlandson M., Smith C. H., Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation 1964 30 698 705 2-s2.0-76549140036
11. Bartfay W. J., Dawood F., Wen W. H., Lehotay D. C., Hou D., Bartfay E., Luo X., Backx P. H., Liu P. P., Cardiac function and cytotoxic aldehyde production in a murine model of chronic iron-overload. Cardiovascular Research 1999 43 4 892 900 2-s2.0-0032853734 10.1016/S0008-6363(99)00040-1 (Pubitemid 29413188)
12. Wood J. C., Cardiac iron across different transfusion-dependent diseases. Blood Reviews 2008 22 supplement 2 S14 S21 2-s2.0-57049104663 10.1016/S0268-960X(08)70004-3
13. Porter J. B., Concepts and goals in the management of transfusional iron overload. American Journal of Hematology 2007 82 12 1136 1139 2-s2.0-36849089638 10.1002/ajh.21100 (Pubitemid 350221244)
14. Oudit G. Y., Trivieri M. G., Khaper N., Liu P. P., Backx P. H., Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. Journal of Molecular Medicine 2006 84 5 349 364 2-s2.0-33646351076 10.1007/s00109-005- 0029-x (Pubitemid 43673610)
15. Hershko C., Link G., Cabantchik I., Pathophysiology of iron overload. Annals of the New York Academy of Sciences 1998 850 191 201 2-s2.0-0031871914 10.1111/j.1749-6632.1998.tb10475.x (Pubitemid 28369759)
16. Randell E. W., Parkes J. G., Olivieri N. F., Templeton D. M., Uptake of non-transferrin-bound iron by both reductive and nonreductive processes is modulated by intracellular iron. Journal of Biological Chemistry 1994 269 23 16046 16053 2-s2.0-0028244452 (Pubitemid 24209290)
17. Tsushima R. G., Wickenden A. D., Bouchard R. A., Oudit G. Y., Liu P. P., Backx P. H., Modulation of iron uptake in heart by L-type Ca2+ channel modifiers: possible implications in iron overload. Circulation Research 1999 84 11 1302 1309 2-s2.0-0033546223 (Pubitemid 29270045)
18. Oudit G. Y., Sun H., Trivieri M. G., Koch S. E., Dawood F., Ackerley C., Yazdanpanah M., Wilson G. J., Schwartz A., Liu P. P., Backx P. H., L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nature Medicine 2003 9 9 1187 1194 2-s2.0-0141461407 10.1038/nm920 (Pubitemid 37173704)
19. Kremastinos D. T., Tsiapras D. P., Tsetsos G. A., Rentoukas E. I., Vretou H. P., Toutouzas P. K., Left ventricular diastolic Doppler characteristics in β -thalassemia major. Circulation 1993 88 3 1127 1135 2-s2.0-0027291579 (Pubitemid 23264030)
20. Olivieri N. F., Brittenham G. M., Matsui D., Berkovitch M., Blendis L. M., Cameron R. G., McClelland R. A., Liu P. P., Templeton D. M., Koren G G., Iron-chelation therapy with oral deferipronein patients with thalassemia major. New England Journal Medicine 1995 332 14 918 922 10.1056/NEJM199504063321404
21. Crowe S., Bartfay W. J., Amlodipine decreases iron uptake and oxygen free radical production in the heart of chronically iron overloaded mice. Biological Research for Nursing 2002 3 4 189 197 2-s2.0-0036527536
22. Kumfu S., Chattipakorn S., Chinda K., Fucharoen S., Chattipakorn N., T-type calcium channel blockade improves survival and cardiovascular function in thalassemic mice. European Journal of Haematology 2012 88 6 535 548 2-s2.0-84859294937 10.1111/j.1600-0609.2012.01779.x
23. Kumfu S., Chattipakorn S., Fucharoen S., Chattipakorn N., Ferric iron uptake into cardiomyocytes of β -thalassemic mice is not through calcium channels. Drug and Chemical Toxicology 2013 36 3 329 334 10.3109/01480545.2012. 726625
24. Jorgensen A. O., Shen A. C.-Y., Arnold W., McPherson P. S., Campbell K. P., The Ca2+-release channel/ryanodine receptor is localized in junctional and corbular sarcoplasmic reticulum in cardiac muscle. Journal of Cell Biology 1993 120 4 969 980 2-s2.0-0027339572 10.1083/jcb.120.4.969 (Pubitemid 23056302)
25. Kim E., Giri S. N., Pessah I. N., Iron(II) is a modulator of ryanodine-sensitive calcium channels of cardiac muscle sarcoplasmic reticulum. Toxicology and Applied Pharmacology 1995 130 1 57 66 2-s2.0-0028817709 10.1006/taap.1995.1008
26. Rose R. A., Sellan M., Simpson J. A., Izaddoustdar F., Cifelli C., Panama B. K., Davis M., Zhao D., Markhani M., Murphy G. G., Striessnig J., Liu P. P., Heximer S. P., Backx P. H., Iron overload decreases CaV1.3-dependent L-type Ca2+ currents leading to bradycardia, altered electrical conduction, and atrial fibrillation. Circulation 2011 4 5 733 742 2-s2.0-84555208189 10.1161/CIRCEP.110.960401
27. Quinlan G. J., Evans T. W., Gutteridge J. M. C., Iron and the redox status of the lungs. Free Radical Biology and Medicine 2002 33 10 1306 1313 2-s2.0-0037111126 10.1016/S0891-5849(02)00903-6 (Pubitemid 35284915)
28. Gao X., Campian J. L., Qian M., Sun X., Eaton J. W., Mitochondrial DNA damage in iron overload. Journal of Biological Chemistry 2009 284 8 4767 4775 2-s2.0-64149103677 10.1074/jbc.M806235200
29. Gao X., Qian M., Campian J. L., Marshall J., Zhou Z., Roberts A. M., Kang Y. J., Prabhu S. D., Sun X., Eaton J. W., Mitochondrial dysfunction may explain the cardiomyopathy of chronic iron overload. Free Radical Biology and Medicine 2010 49 3 401 407 2-s2.0-77954145905 10.1016/j.freeradbiomed.2010.04.033
30. Jackson J. H., Schraufstatter I. U., Hyslop P. A., Vosbeck K., Sauerheber R., Weitzman S. A., Cochrane C. G., Role of oxidants in DNA damage. Hydroxyl radical mediates the synergistic DNA damaging effects of asbestos and cigarette smoke. Journal of Clinical Investigation 1987 80 4 1090 1095 2-s2.0-0023607544 (Pubitemid 18075647)
31. Schraufstatter I., Hyslop P. A., Jackson J. H., Cochrane C. G., Oxidant-induced DNA damage of target cells. Journal of Clinical Investigation 1988 82 3 1040 1050 2-s2.0-0023713873
32. Enright H. U., Miller W. J., Hebbel R. P., Nucleosomal histone protein protects DNA from iron-mediated damage. Nucleic Acids Research 1992 20 13 3341 3346 2-s2.0-0026762795
33. Enright H., Nath K. A., Hebbel R. P., Schrier S. L., Internucleosomal cleavage of DNA is insufficient evidence to conclude that cell death is apoptotic. Blood 1994 83 7 2005 2007 2-s2.0-0028221773 (Pubitemid 24107929)
34. Yakes F. M., Van Houten B., Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proceedings of the National Academy of Sciences of the United States of America 1997 94 2 514 519 2-s2.0-0031032817 10.1073/pnas.94.2.514 (Pubitemid 27053665)
35. Salazar J. J., Van Houten B., Preferential mitochondrial DNA injury caused by glucose oxidase as a steady generator of hydrogen peroxide in human fibroblasts. Mutation Research 1997 385 2 139 149 2-s2.0-0031441858 10.1016/S0921-8777(97)00047-5 (Pubitemid 28026803)
36. Shvartsman M., Kikkeri R., Shanzer A., Cabantchik Z. I., Non-transferrin-bound iron reaches mitochondria by a chelator-inaccessible mechanism: biological and clinical implications. American Journal of Physiology 2007 293 4 C1383 C1394 2-s2.0-35048833703 10.1152/ajpcell.00054.2007 (Pubitemid 47556747)
37. Shvartsman M., Fibach E., Cabantchik Z. I., Transferrin-iron routing to the cytosol and mitochondria as studied by live and real-time fluorescence. Biochemical Journal 2010 429 1 185 193 2-s2.0-77954474798 10.1042/BJ20100213
38. Bolli R., Patel B. S., Zhu W.-X., O'Neill P. G., Hartley C. J., Charlat M. L., Roberts R., The iron chelator desferrioxamine attenuates postischemic ventricular dysfunction. American Journal of Physiology 1987 253 6 H1372 H1380 2-s2.0-0023571583
39. van der Kraaij A. M. M., van Eijk H. G., Koster J. F., Prevention of postischemic cardiac injury by the orally active iron chelator 1,2-dimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)-cyanidanol-3. Circulation 1989 80 1 158 164 2-s2.0-0024402583 (Pubitemid 19178649)
40. Lian W. S., Lin H., Cheng W. T. K., Kikuchi T., Cheng C. F., Granulocyte-CSF induced inflammation-associated cardiac thrombosis in iron loading mouse heart and can be attenuated by statin therapy. Journal of Biomedical Science 2011 18 26 2-s2.0-79955100019 10.1186/1423-0127-18-26
41. Harada M., Qin Y., Takano H., Minamino T., Zou Y., Toko H., Ohtsuka M., Matsuura K., Sano M., Nishi J., Iwanaga K., Akazawa H., Kunieda T., Zhu W., Hasegawa H., Kunisada K., Nagai T., Nakaya H., Yamauchi-Takihara K., Komuro I., G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nature Medicine 2005 11 3 305 311 2-s2.0-20144388775 10.1038/nm1199 (Pubitemid 40460559)
42. Minatoguchi S., Takemura G., Chen X., Wang N., Uno Y., Koda M., Arai M., Misao Y., Lu C., Suzuki K., Goto K., Komada A., Takahashi T., Kosai K., Fujiwara T., Fujiwara H., Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment. Circulation 2004 109 21 2572 2580 2-s2.0-2642517975 10.1161/01.CIR.0000129770.93985.3E (Pubitemid 38720559)
43. Ohtsuka M., Takano H., Zou Y., Toko H., Akazawa H., Qin Y., Suzuki M., Hasegawa H., Nakaya H., Komuro I., Cytokine therapy prevents left ventricular remodeling and dysfunction after myocardial infarction through neovascularization. The FASEB Journal 2004 18 7 851 853 2-s2.0-4644247808
44. Deindl E., Zaruba M., Brunner S., Huber B., Mehl U., Assmann G., Hoefer I. E., Mueller-Hoecker J., Franz W., G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis. The FASEB Journal 2006 20 7 956 958 2-s2.0-33744457696 10.1096/fj.05-4763fje (Pubitemid 44961988)
45. Li L., Takemura G., Li Y., Miyata S., Esaki M., Okada H., Kanamori H., Ogino A., Maruyama R., Nakagawa M., Minatoguchi S., Fujiwara T., Fujiwara H., Granulocyte colony-stimulating factor improves left ventricular function of doxorubicin-induced cardiomyopathy. Laboratory Investigation 2007 87 5 440 455 2-s2.0-34247349564 10.1038/labinvest.3700530 (Pubitemid 46633120)
46. Day S. M., Duquaine D., Mundada L. V., Menon R. G., Khan B. V., Rajagopalan S., Fay W. P., Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis. Circulation 2003 107 20 2601 2606 2-s2.0-0038350932 (Pubitemid 36628943)
47. Cheng Z., Ou L., Liu Y., Liu X., Li F., Sun B., Che Y., Kong D., Yu Y., Steinhoff G., Granulocyte colony-stimulating factor exacerbates cardiac fibrosis after myocardial infarction in a rat model of permanent occlusion. Cardiovascular Research 2008 80 3 425 434 2-s2.0-56549096399 10.1093/cvr/cvn202
48. Cheng Z., Liu X., Ou L., Zhou X., Liu Y., Jia X., Zhang J., Li Y., Kong D., Mobilization of mesenchymal stem cells by granulocyte colony-stimulating factor in rats with acute myocardial infarction. Cardiovascular Drugs and Therapy 2008 22 5 363 371 2-s2.0-51349089610 10.1007/s10557-008-6110-2
49. Stoyanova E., Cloutier G., Felfly H., Lemsaddek W., Ah-Son N., Trudel M., Evidence for a novel mechanism independent of myocardial iron in beta-thalassemia cardiac pathogenesis. PloS ONE 2012 7 e52128
50. Skow L. C., Burkhart B. A., Johnson F. M., A mouse model for β -thalassemia. Cell 1983 34 3 1043 1052 2-s2.0-0020564074
51. Stoyanova E., Trudel M., Felfly H., Garcia D., Cloutier G., Characterization of circulatory disorders in β -thalassemic mice by noninvasive ultrasound biomicroscopy. Physiological Genomics 2007 29 1 84 90 2-s2.0-34248143313 10.1152/physiolgenomics.00305.2005 (Pubitemid 46708765)
52. Mattera R., Stone G. P., Bahhur N., Kuryshev Y. A., Increased release of arachidonic acid and eicosanoids in iron-overloaded cardiomyocytes. Circulation 2001 103 19 2395 2401 2-s2.0-0035873949 (Pubitemid 32448806)
53. Johnson G. III, Furlan L. E., Aoki N., Lefer A. M., Endothelium and myocardial protecting actions of taprostene, a stable prostacyclin analogue, after acute myocardial ischemia and reperfusion in cats. Circulation Research 1990 66 5 1362 1370 2-s2.0-0025214616 (Pubitemid 20147752)
54. Lin H., Li H. F., Lian W. S., Chen H. H., Lan Y. F., Lai P. F., Cheng C. F., Thromboxan A2 mediates iron-overload cardiomyopathy in mice through calcinurin-NFAT signaling pathway. Circulation Journal 2013 77 10 2586 2595 10.1253/circj.CJ-12-1516
55. Cyrus T., Ding T., Praticò D., Expression of thromboxane synthase, prostacyclin synthase and thromboxane receptor in atherosclerotic lesions: correlation with plaque composition. Atherosclerosis 2010 208 2 376 381 2-s2.0-75049084888 10.1016/j.atherosclerosis.2009.08.008
56. Forouhi N. G., Harding A. H., Allison M., Sandhu M. S., Welch A., Luben R., Bingham S., Khaw K. T., Wareham N. J., Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia 2007 50 5 949 956 2-s2.0-34147175589 10.1007/s00125-007- 0604-5 (Pubitemid 46559245)
57. Mojiminiyi O. A., Marouf R., Abdella N. A., Body iron stores in relation to the metabolic syndrome, glycemic control and complications in female patients with type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases 2008 18 8 559 566 2-s2.0-51249096123 10.1016/j.numecd.2007.07.007
58. Ku B. J., Kim S. Y., Lee T. Y., Park K. S., Serum ferritin is inversely correlated with serum adiponectin level: population-based cross-sectional study. Disease Markers 2009 27 6 303 310 2-s2.0-77249138221 10.3233/DMA-2009-0676
59. Gabrielsen J. S., Gao Y., Simcox J. A., Huang J., Thorup D., Jones D., Cooksey R. C., Gabrielsen D., Adams T. D., Hunt S. C., Hopkins P. N., Cefalu W. T., McClain D. A., Adipocyte iron regulates adiponectin and insulin sensitivity. The Journal of Clinical Investigation 2012 122 10 3529 3540 10.1172/JCI44421
60. Kahn E., Baarine M., Pelloux S., Riedinger J., Frouin F., Tourneur Y., Lizard G., Iron nanoparticles increase 7-ketocholesterol-induced cell death, inflammation, and oxidation on murine cardiac HL1-NB cells. International Journal of Nanomedicine 2010 5 1 185 195 2-s2.0-77951147584
61. Lin H., Lian W. S., Chen H. H., Lai P. F., Cheng C. F., Adiponectin ameliorates iron-overload cardiomyopathy through the PPAR α -PGC-1-dependent signaling pathway. Molecular Pharmacology 2013 84 2 275 285 10.1124/mol.112.083964
62. Davignon J., Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004 109 23 III39 III43 2-s2.0-2942720515 (Pubitemid 38786442)
63. Liao J. K., Laufs U., Pleiotropic effects of statins. Annual Review of Pharmacology and Toxicology 2005 45 89 118 2-s2.0-10644286120 10.1146/annurev.pharmtox.45.120403.095748 (Pubitemid 40261799)
64. Grandel U., Fink L., Blum A., Heep M., Buerke M., Kraemer H.-J., Mayer K., Bohle R. M., Seeger W., Grimminger F., Sibelius U., Endotoxin-induced myocardial tumor necrosis factor- α synthesis depresses contractility of isolated rat hearts: evidence for a role of sphingosine and cyclooxygenase-2- derived thromboxane production. Circulation 2000 102 22 2758 2764 2-s2.0-0034727713
65. Katagiri H., Ito Y., Ito S., Murata T., Sugimoto Y., Narumiya S., Watanabe M., Majima M., TNF- α induces thromboxane receptor signaling-dependent microcirculatory dysfunction in mouse liver. Shock 2008 30 4 463 467 2-s2.0-54049158457 10.1097/SHK.0b013e3181673f54